Leerink on Compass Therapeutics (CMPX): 'there are multiple sources of long-term upside'
Tweet Send to a Friend
Leerink Partners analyst Andrew Berens reiterated an Outperform rating and $11.00 price target on Compass Therapeutics (NASDAQ: CMPX).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
